While these executives and directors bring tremendous pharmaceutical and vaccine experience to Oragenics, we have also engaged advisors to help us navigate research and development, manufacturing, and regulatory pathways.
Terrence (Terry) Cochrane
Terrence (Terry) Cochrane is President of BrevisRefero Corporation in Ontario, Canada. Mr. Cochrane brings decades of life sciences industry experience to Oragenics, with over 20 years of progressive management experience in biopharmaceutical development and the GMP manufacturing industry for biologic therapies and vaccines. BrevisRefero provides biopharma outsourcing assistance in identifying and selecting service providers and follow-on technical program management to facilitate the delivery of products to clinic and market. Mr. Cochrane holds a B.S. from the University of Winnipeg in Biochemistry and Biology.
Timothy Cooke, Ph.D.
Dr. Cooke has more than 30 years of vaccine development experience in early- to late-stage research and development programs. Dr. Cooke’s experience includes 20 years at Merck, where he helped to develop several blockbuster vaccines. Dr. Cooke has been a vaccine development consultant to MNCs, small biotechs and NGOs around the world for more than 10 years.
David Zarley, PhD
Dr. David Zarley has more than 30 years of experience in vaccine research and development in the private sector, including as a consultant to Noachis Terra. Dr. Zarley was Vice President of Program Management for Vaccine Research and Development at Pfizer and Senior Director and Medicines Team Leader for the Pfizer Primary Care Business Unit. Dr. Zarley was also Senior Director for the Wyeth Research Project Management Business Unit and Senior Director for Technical Operations and Product Supply at Wyeth Vaccines. Dr. Zarley’s experience also includes work as a Senior Research Biochemist and Project Leader for Viral Vaccine Research and Development at Lederle-Praxis Biologicals. Dr. Zarley received his PhD in Molecular, Cellular, and Development Biology from Indiana University.
Oragenics has a third independent advisor with more than 30 years of vaccine development experience in early- to late-stage research and development programs, including technology transfer of projects along the continuum from academic labs to industry research labs, and development labs to manufacturing and quality control settings. This advisor spent nearly 20 years at Merck, helping to develop several blockbuster vaccines, and has been a vaccine development consultant to MNCs, small biotechs, and NGOs around the world for more than 10 years.